India, Aug. 3 -- Key Highlights
* Positive Phase 2 HORIZON topline results for MZE829 in APOL1-mediated kidney disease (AMKD). * Continued advancement of the MZE782 pipeline toward Phase 2 development in PKU and CKD. * Initiation of the Phase 2 ESPRIT trial for partnered candidate S-606001 (previously known as MZE001), triggering a $20 million milestone payment from Shionogi.
Maze Therapeutics Inc. (MAZE) is a clinical-stage biopharmaceutical company developing a drug for APOL1-mediated kidney disease (AMKD) for which there are currently no FDA-approved therapies.
For comments and feedback contact: editorial@rttnews.com
Published by HT Digital Content Services with permission from RTT News....